TRUE-AHFInvestigating ularitide:the �rst prospective Phase III mortality trial in acute heart failure

Study Chair: Milton Packer, MD

www.cardiorentis.com

TRUE-AHFTRial of Ularitide’s E�cacy and safety in patients with Acute Heart Failure

The TRUE-AHF trial is a phase III, multicenter, ran-domized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of Ularitide (Urodi-

latin) intravenous infusion in addition to conventional therapy in patients suffering from acute decompensated heart failure in addition to conventional therapy.

* Investigational drug; limited by United States law to

investigational use only.

2

Study Status

The study is currently recruiting subjects in over 190 clinical sites in over 23 countries: Germany, France, Finland, Italy, Switzerland, Netherlands, Spain, Tunisia, Hungary, Poland, Czech Rep., Estonia, Turkey, Romania, Serbia, Latvia, Lithua-nia, USA, Canada, Colombia, Argentina, Chile, Brazil.

3

Study Overview

Primary E�cacy Endpoint; There are two co-primary endpoints. Coprimary efficacy endpoint 1 evaluates chan-ges in a hierarchical clinical composite comprising patient global assessment using a 7-point scale of symptomatic im-provement, lack of improvement, or worsening; persistent or worsening heart failure (HF) requiring initiation or intensifi-cation of IV therapy, circulatory or ventilatory mechanical support, surgical intervention, ultrafi ltration, hemofi ltration or dialysis; and all-cause mortality. Assessment of the clini-cal composite will be performed at 6 hour (h), 24h and 48h after start of IV ularitide infusion. Patients will be classified as

“improved” if the patients are moderately or markedly im-proved at all 3 time points (at 6h, 24h and 48h) and do not fulfill criteria for “worse” during the first 48 hours following the start of the study drug infusion. Patients will be classified as “worse” if (during the 48h) they die; experience persistent or worsening HF requiring a pre-specified intervention at any time during the first 48h; or experienced moderate or mar-ked worsening of their global assessment at any of the 3 time points (at 6h, 24h or 48h). Co-primary efficacy endpoint 2 evaluates cardiovascular mortality during follow-up after ran-domization, for the entire duration of the trial.

Key Inclusion Criteria:1) Males and females aged 18 to 85 years.2) Unplanned hospitalization or emergency department

visit for ADHF. Acute HF is defined as including all of the following:a) Dyspnea at rest in a recumbent sitting position (30 to

45 degrees), which has worsened within the past week.b) Radiological evidence of HF on a chest X-ray.c) BNP >500 pg/mL or NT-pro BNP >2000 pg/mL.

3) Ability to start infusion of the study drug within 12h after initial clinical assessment performed by a physician at the emergencyroom/hospital with symptoms of ADHF.

4) Ability to reliably carry out self-assessment of symptoms.5) Systolic blood pressure (SBP) ≥110 mmHg.

6) Persisting dyspnea at rest despite standard background therapy for ADHF (as determined by the Investigator) which must include IV furosemide (or equivalent diuretic) at ≥ 40 mg (or its equivalent) at any time after start of emergency services (ambulance, emergency depart-ment, or hospital). At the time of randomization, the pati-ent must still be symptomatic. In addition, the patient should not have received an IV bolus of a diuretic for at least 2h prior to randomization, and the infusion rates of ongoing IV infusions must not have been increased or decreased for at least 2h prior to randomization.

7) Ability to understand the purpose and risks of the study and provide signed and dated informed consent and au-thorization to use protected health information (in accor-dance with national and local privacy regulations).

Ularitide i.v., 15ng/kg/min (n = 1,076)

48h study drug infusion Post-discharge evaluations

0 6h 12h 24h 48h 60h 72h 120h 30 days 60 days 90 days ... end of study

Aim and Study Design

Cardiovascular reshospitalization until day 180 & cardiovascular mortality for the entire duration of the trial

Placebo i.v. (n = 1,076)

Estimated no. patients: 2,152

Randomization (n = 2,152 patients); Hospitalized patients with AHF

Ularitide for Injection*

Ularitide is the chemically synthesized form of urodilatin, a human, 32-amino acid natriuretic peptide that is pro-duced in the kidneys and found primarily in urine and in very low concentrations in blood plasma.

Under physiologic conditions the endogenous peptide functions purely as an intrarenal paracrine factor. It in-duces natriuresis and diuresis by binding to the natriu-retic peptide receptor in the cortical and inner medullary collecting duct, thereby increasing intracellular levels of cyclic guanosine monophosphate (cGMP).

Broader systemic effects as a potent vasodilatatory agent are achieved when the synthetic peptide Ularitide is infused into the circulation.

References: Mitrovic V, Seferovic P, Simeunovic D, et al. Haemodynamic and clinical effects of Ularitide in

decompensated heart failure.European Heart Journal 2006;27:2823–2832

Subject Identification

PHASE IIIProtocol Pathway ULA01 – TRUE-AHF

Key Inclusion Criteria

Unplanned hospitalization or ER visit for ADHF Dyspnea at rest Radiological evidence of HF on chest X-Ray BNP > 500 pg/mL or NT-pro BNP > 2000 pg/mL Ability to start infusion of the study drug within 12 hrs after initial clinical assessment (ER/hospital)

Ability to reliably carry out self-assessment of symptoms

Systolic blood pressure (SBP) ≥ 110 mmHg Received IV furosemide ≥ 40 mg (or its equivalent)

3

Key Exclusion Criteria

Suspected acute mechanical cause of ADHF Clinical diagnosis of ACS Planned PCI or CABG within 5 days of randomization Treatment with nesiritide within last 30 days Treatment with dobutamine at a dose > 5 μg/kg/min or use of drugs for support of blood pressure

Treatment with levosimendan, milrinone, or PDE inhibitor within last 7 days

Temperature ≥ 38°C Suspected infections including pneumonia and acute hepatitis

Known vasculitis, active infective endocarditis Acute or chronic respiratory disorder or primary pulmonary hypertension that may interfere with the ability to interpret dyspnea assessment

Serum creatinine > 2.5 mg/dL Anemia (hemoglobin < 9 g/dL or a hematocrit < 25%)

Any previous exposure to Ularitide

Acute Decompensated Heart Failure

ER (Cardiologists/Intensivists)Study

Timeline

Consent

Screening Exams

Randomization

X-Ray; BNP/NT-proBNP; Labs; ECG

Consent to study

Patient randomized

Targeted T < 6 hours(Tmax < 12 hours)The targeted time to Ularitide (TTU) is below 6 hours after the first physician assessment; treatment must be started within 12 hours of initial assessment (ER/Hospital)

6hMax.12 hours

Prospective, Treatment*,Randomized,Double-Blind

*Treatment will be administered

on top of standard treatment

Ularitide, IV 15ng/kg/min

48 hours

Placebo, IV

Final assessment at 72 hours or hospitaldischarge, whichever comes first

Follow-UpPhone follow-ups to assess cardiovascular

hospitalisation and deathDay 30, 60, 90,

180 and EOS

Disclaimer: Patient pathways are tools and not intended to replace the protocol. For a complete overview of the inclusion and

exclusion criteria please refer to the protocol.5

Challenges for Recruitment

Close collaboration between ER and cardiologist Time to treatment window Targeted Time to Ularitide (TTU) < 6 hours, Tmax < 12 hours

Trained personnel 24/7 availability

Primary Efficacy EndpointHierarchical Composite

Death Worsening HF requiring intervention Patient Global Assessment Cardiovascular Mortality

2152 subjects randomized Ularitide : Placebo = 1 : 13d-Model of Ularitide

6

Study Design

Patients with ADHF who meet all inclusion and exclusioncriteria will be randomized on a 1:1 basis to continuous IV infusion of either ularitide 15 ng/kg BW/min or matching placebo for 48 h. In addition, patients may receive all appropriate therapy that may include vasodi-latory, inotropic, and diuretic support as clinically indica-ted. However, use of nesiritide, levosimendan, milrinone, or any other phosphodiesterase inhibitor is not allowed during the first 72 h following the start of the infusion.

All timepoints refer to the start of the study drug infu-sion at the timepoint called “0 hours” (t0). Co-primary efficacy endpoint 1 will be assessed at 6 h, 24 h and 48

h from the start of infusion Co-primary efficacy endpoint 2 evaluates cardiovascular mortality during follow-up af-ter randomization, for the entire duration of the trial.

Safety parameters will be assessed during the index hospitalization and adverse events (AEs) and serious ad-verse events (SAEs) will be evaluated until Day 30 after the start of therapy. All patients will be assessed through a study visit at Day 30 and phone call follow-ups at Day 60, Day 90 and Day 180 for the occurrence of cardiova-scular rehospitalization and allcause mortality. After Day 180, patients will be contacted every 3 months until the end of the study, in order to assess all-cause mortality.

Independent Committees

All outcomes associated with the primary endpoints will be adjudicated by an independent Clinical Events Committee (CEC). In addition, all cardiovascular hospita-lizations and deaths recorded during the 180-day fol-low-up period will be adjudicated.

An independent Data and Safety Monitoring Board (DSMB) will monitor all efficacy and safety outcomes, but will be able to recommend early termination of the trial for benefit only for a favorable effect of treatment on car-diovascular mortality.

If the patient dies during the first 48h

If the patient experiences persistent or worsening HF suffi cient to require inter-

vention (e.g. initiation/ increase of IV therapy,

circulatory or ventilatory mechanical support, surgery, ultrafi ltration, hemofiltration,

dialysis) during first 48h

If the patient experiences worsening global assessment

at 6, 24 OR 48h

If the patient experiences moderate to marked impro-vement in global assessment

at 6, 24 AND 48h

No

WORSEYes

No

No

No

WORSEYes

WORSEYes

IMPROVEDYes

NO CHANGE

Cardiorentis AGSteinhauserstrasse 74

6300 Zug / Switzerlandwww.cardiorentis.com

Phone +41 41 748 6030FAX +41 41 748 6031

Email info@cardiorentis.com

www.cardiorentis.com